A Novel Substrate to Amplify Growth Factor Impact on hPSC Differentiation

Period of Performance: 04/01/2014 - 03/31/2015

$225K

Phase 1 SBIR

Recipient Firm

Primorigen Biosciences, Inc.
Madison, WI 53719
Principal Investigator

Abstract

DESCRIPTION (provided by applicant): Primorigen Biosciences(R) Project Abstract Primorigen will use SBIR funds to develop a paradigm-changing technology for expansion and directed differentiation of human pluripotent stem cells (hPSCs) using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and minimizing the need for exogenous growth factors. The peptide has been used to amplify the physiological effects of multiple growth factors, through mechanisms described in the proposal. Phase I studies will demonstrate the utility of the peptide on standard polystyrene culture vessels to enhance proliferation of hiPSCs in reduced growth factor-containing serum-free media, and to serve as an effective agent for more cost-efficient directed differentiation. We will demonstrate the latter feasibility by using Primorigen's proprietary, high efficiency hepatocyte differentiation protocol for differentiation of hiPSCs on the peptide-modified surfaces, providing proof of principle for extending the technology to other lineages. Phase II activities will test an validate the peptide for use in 1) scaled-up production of hiPSCs on microcarriers in stirred-cell suspension bioreactors, 2) effective growth-factor dependent differentiation of other lineages in the presence of the peptide, to accompany scale-up. Products developed from this proposal will include the peptide-coated cultureware along with companion, reduced growth factor media for hiPSC maintenance and differentiation into various cell types, beginning with hepatocytes.